Vertakova-Krakovska and Vanovcanova reported that 31 IBC patients underwent pre-treatment core-cut, punch skin biopsy, and MRI in response to neoadjuvant chemotherapy (NAC) (doxorubicin and/or taxane regimen, HER2+ with trastuzumab if applicable). This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.